# Rockwell Medical, Inc.: overview RMTI · Nasdaq · CIK 1041024 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rmti.md) · [Financials](/companies/rmti/financials.md) · [Filings](/companies/rmti/filings.md) · [Insiders](/companies/rmti/insiders.md) Latest reported revenue: [$17.8m](/filings/0001628280-26-056461.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001628280-26-056461). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [28.3](/filings/0001628280-25-051290.md) | [24.7 d](/filings/0001628280-26-021186.md) | [18.9](/filings/0001628280-26-031663.md) | [16.1](/filings/0001628280-26-056461.md) | [15.9](/filings/0001628280-25-051290.md) | [18.3 d](/filings/0001628280-26-021186.md) | [17.3](/filings/0001628280-26-031663.md) | [17.8](/filings/0001628280-26-056461.md) | | Gross margin | % | [22.0%](/filings/0001628280-25-051290.md) | [14.7% d](/filings/0001628280-26-021186.md) | [16.1%](/filings/0001628280-26-031663.md) | [15.6%](/filings/0001628280-26-056461.md) | [14.3%](/filings/0001628280-25-051290.md) | [21.1% d](/filings/0001628280-26-021186.md) | [16.7%](/filings/0001628280-26-031663.md) | [18.2%](/filings/0001628280-26-056461.md) | | Operating margin | % | [6.8%](/filings/0001628280-25-051290.md) | [(2.1%) d](/filings/0001628280-26-021186.md) | [(7.2%)](/filings/0001628280-26-031663.md) | [(8.4%)](/filings/0001628280-26-056461.md) | [(9.9%)](/filings/0001628280-25-051290.md) | [(2.2%) d](/filings/0001628280-26-021186.md) | [(8.5%)](/filings/0001628280-26-031663.md) | [(6.0%)](/filings/0001628280-26-056461.md) | | Net margin | % | [5.9%](/filings/0001628280-25-051290.md) | [(3.1%) d](/filings/0001628280-26-021186.md) | [(8.0%)](/filings/0001628280-26-056461.md) | [(9.3%)](/filings/0001628280-26-056461.md) | [(11.0%)](/filings/0001628280-25-051290.md) | [(3.0%) d](/filings/0001628280-26-021186.md) | [(9.3%)](/filings/0001628280-26-056461.md) | [(6.6%)](/filings/0001628280-26-056461.md) | | Diluted EPS | $ per share | [0.04](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | [(0.05)](/filings/0001041024-25-000011.md) | [(0.05)](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | not reported | | Free cash flow | $m | [4.1 d](/filings/0001628280-25-051290.md) | [0.5 d](/filings/0001628280-26-021186.md) | [(3.6)](/filings/0001628280-26-031663.md) | [1.7 d](/filings/0001628280-26-056461.md) | [(1.5) d](/filings/0001628280-25-051290.md) | [2.2 d](/filings/0001628280-26-021186.md) | [(0.6)](/filings/0001628280-26-031663.md) | [1.5 d](/filings/0001628280-26-056461.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [61.9](/filings/0001628280-23-009774.md) | [72.8](/filings/0001628280-24-012572.md) | [83.6](/filings/0001628280-25-013983.md) | [101](/filings/0001628280-26-021186.md) | [69.3](/filings/0001628280-26-021186.md) | | Gross margin | % | [(3.9%)](/filings/0001628280-23-009774.md) | [5.6%](/filings/0001628280-24-012572.md) | [10.4%](/filings/0001628280-25-013983.md) | [17.2%](/filings/0001628280-26-021186.md) | [16.9%](/filings/0001628280-26-021186.md) | | Operating margin | % | [(49.0%)](/filings/0001628280-23-009774.md) | [(23.0%)](/filings/0001628280-24-012572.md) | [(8.0%)](/filings/0001628280-25-013983.md) | [0.6%](/filings/0001628280-26-021186.md) | [(6.8%)](/filings/0001628280-26-021186.md) | | Net margin | % | [(52.8%)](/filings/0001628280-23-009774.md) | [(25.7%)](/filings/0001628280-24-012572.md) | [(10.1%)](/filings/0001628280-25-013983.md) | [(0.5%)](/filings/0001628280-26-021186.md) | [(7.7%)](/filings/0001628280-26-021186.md) | | Diluted EPS | $ per share | [(3.83)](/filings/0001628280-23-009774.md) | [(1.31)](/filings/0001628280-24-012572.md) | [(0.37)](/filings/0001628280-25-013983.md) | [(0.03)](/filings/0001628280-26-021186.md) | [(0.15)](/filings/0001628280-26-021186.md) | | Free cash flow | $m | not reported | not reported | [(9.7)](/filings/0001628280-25-013983.md) | [3.2](/filings/0001628280-26-021186.md) | [(1.2)](/filings/0001628280-26-021186.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rmti/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HARBOUR INVESTMENTS, INC.](/funds/810121.md) | 2026-06-30 | $12.0k | 21,865 | | New +21,865 | | [COMPASS FINANCIAL MANAGEMENT LLC](/funds/2148724.md) | 2026-06-30 | $91 | 12 | | Not compared | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $37 | 67 | | New +67 | ## Recent filings [All 1,049 filings](/companies/rmti/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 11:27 ET | [8-K](/filings/0001628280-26-056470.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-056470 | | 2026-08-13 | 10:59 ET | [10-Q](/filings/0001628280-26-056461.md) | Quarterly report, period 2026-06-30 | 0001628280-26-056461 | | 2026-08-13 | 10:14 ET | [8-K](/filings/0001628280-26-056454.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056454 | | 2026-07-20 | 10:22 ET | [8-K](/filings/0001628280-26-048752.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-048752 | | 2026-06-29 | 10:17 ET | [8-K](/filings/0001628280-26-045866.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001628280-26-045866 | | 2026-06-15 | 20:27 ET | [8-K](/filings/0001628280-26-043210.md) | 5.07 Shareholder vote results | 0001628280-26-043210 | | 2026-05-08 | 21:00 ET | [8-K](/filings/0001628280-26-032987.md) | 3.01 Delisting notice | 0001628280-26-032987 | | 2026-05-07 | 11:14 ET | [8-K](/filings/0001628280-26-031680.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-031680 | | 2026-05-07 | 10:59 ET | [10-Q](/filings/0001628280-26-031663.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031663 | | 2026-05-07 | 10:16 ET | [8-K](/filings/0001628280-26-031629.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031629 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-021186.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/068c4e2b-5ceb-4f36-be8e-8c9b2547fd71) ## About the filer - CIK: 1041024 - Tickers: RMTI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.